This award is for the delivery of a cgmp manufactured product of quantity and quality that IT is suitable and appropriate for use in pivotal clinical studies to demonstrate efficacy against

Active Definitive Contract Awarded Last action

Contract number
W81XWH20C0137
Awardee
Awarding agency
Obligated
$40,613,408

Award facts

Opportunity
Contract value 79% obligated
$51,663,681.78 Current and potential, with all options
Completion date 76% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Fixed Price Level of Effort
Place of performance
Sweden

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00012 · This contract action is for diarrhea prevention for tactical environments (DPTE). $0
Funding Only Action P00011 · Vaccine development $1,182,300
Supplemental Agreement for work within scope P00010 · Diarrhea prevention for tactical environments $0
Funding Only Action P00009 · This contract action is for diarrhea prevention for tactical environments (DPTE). $433,301
Supplemental Agreement for work within scope P00008 · Contract for diarrhea prevention for tactical environments testing and manufacture. $46,000
Supplemental Agreement for work within scope P00007 · This requirement is for the research and production of an enterotoxigenic E. Coli vaccine to help reduce warfighter down time when serving in theatre. $606,000
Supplemental Agreement for work within scope P00006 · This contract is for the development of an E. Coli vaccine for FDA approval. $20,479,340
Supplemental Agreement for work within scope P00005 · Enterotoxigenic E. Coli vaccine development. $254,430
Other Administrative Action P00004 · Base task - subcontractors $0
Supplemental Agreement for work within scope P00003 · E. Coli vaccine development. $5,186,161
Supplemental Agreement for work within scope P00002 · Further development of etvax, a vaccine against enterotoxigenic escherichia coli (ETEC). $4,306,102
Other Administrative Action P00001 · Admin MOD changing several deliverable due dates found in the award caused by a delayed contract kickoff meeting. $0
Original award $8,119,774
Show all 13

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded a $51.66 million definitive contract to Scandinavian Biopharma Holding AB on September 25, 2020, for the delivery of a current good manufacturing practice (CGMP) manufactured product suitable for use in pivotal clinical studies to demonstrate efficacy against enterotoxigenic E. coli (ETEC) in adults, with the goal of FDA licensure.

The contract supports the Diarrhea Prevention for Tactical Environments (DPTE) program. Place of performance is Sweden. The contract carries a fixed-price level-of-effort pricing structure and extends through September 30, 2028.

Quick answers

Who was awarded contract W81XWH20C0137?

W81XWH20C0137 was awarded to Scandinavian Biopharma Holding AB by Defense Health Agency (Department of Defense) on September 25, 2020.

How much is contract W81XWH20C0137 worth?

The government has obligated $40,613,408 on W81XWH20C0137. Its current value, with exercised options, is $51,663,682.

Was contract W81XWH20C0137 competed?

The extent of competition for W81XWH20C0137 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login